A Summary of Recent Drug Repurposing Patent Applications (Part II)

We continue our series with a summary of the Q1/2019 drug repurposing patent discussions in ASSAY and Drug Development Technologies (ahead of print, DOI link here).

 

  • WO/2019/004808 (Université Mohammed V Rabat (Morocco)

Pyridostigmin restores peripheral nervous system balance in neurodegenerative diseases or after neurotrauma

  • WO/2019/008141 INSERM, CNRS, Université Paris Descartes (France)

Some phenothiazines carrying a piperidine or piperazine substituent (thioridazine, mesoridazine, trifluoroperazine and others) induce efficient dispersal of meningococcal aggregates at low micromolar concentrations

  • WO/2019/012109 (Paris Sciences et Lettres et al., France)

Probenecid, an old gout drug that inhibits organic anion transporters recently reported to have considerable drug repurposing potential in traumatic nerve injury and (more indirectly) in viral infections, is effective in the kainate mouse model of temporal lobe epilepsy

  • WO/2019/016357 (Neurolexis, France; Uniwersytet Jagiellonski Collegium Medicum, Poland)

Selective serotonin 5-HT1a receptor agonists (flibanserin, flesinoxan, saritozan, befiradol, valbenazine, tetrabenazine) can treat side effects of vesicular monoamine transport inhibitors used in Parkinson disease

  • WO/2019/020634 (Institut d’Investigació Biomédica de Bellvitge, Spain)

Clenbuterol is a long-acting beta2 adrenergic receptor agonist used for asthma, preserves renal function in a mouse model of systemic lupus

  1. WO/2019/028234 (Ovid Therapeutics Inc., USA)

Monotherapy with the GABAA receptor, gaboxadol at 5 mg, 10 mg and 20-mg doses will be tested in diabetic patients vs. placebo over a 6-month period

  • WO/2019/030151 (Consejo Superior de Investigaciones Científicas and Alianza Española de Familias de von Hippel-Lindau-VHL, Spain)

ICI 118,551, a decades-old discontinued compound that is now used as a research tool for beta2 receptor blockade, for von Hippel-Lindau disease; butoxamine and prenalterol are also claimed

  • WO/2019/036363 (Progenity Inc., USA)

Clever device technology enables repurposing of the MS drug, glatiramer acetate to treat inflammatory bowel diseases

  • WO/2019/040706 (Aclaris Therapeutics, Inc., USA)

JAK/STAT inhibitors for vitiligo, a physically harmless but disfiguring skin disorder

  • WO/2019/041404 (Hangzhou DC Pharmaceutical Co. Ltd., China)

Claiming inhalable formulations of zoledronate for COPD and/or asthma

  • WO/2019/046959 (UTI Limited Partnership, Canada)

The antidepressant, mirtazapine might treat rimary biliary cholangitis via Kupffer cells

  • WO/2019/060171 (Calista Capital, LLC, USA)

Cefdinir, a third generation semisynthetic cephalosporin antibiotic, for smoking cessation – quite like its close relative, ceftriaxone – via the GLT-1 glutamate transporter?

Leave a Reply

Your email address will not be published. Required fields are marked *